Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Agios Pharmaceuticals to lay off 50 researchers

by Jessica Marshall
May 20, 2022 | A version of this story appeared in Volume 100, Issue 18

 

Agios Pharmaceuticals is adding to mounting layoffs in the biotech sector. The Massachusetts-based company says it will eliminate as many as 50 employees—primarily in exploratory research—out of a workforce of nearly 400. It will retain staff working on later-stage drugs in its pipeline, which targets sickle cell disease, pediatric pyruvate kinase deficiency, thalassemia, and other genetically defined conditions. Agios has an approved drug to treat adult pyruvate kinase deficiency.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.